Study Suggests Long-lasting Protection from COVID-19 Vaccine

John Whyte, MD; Rachel Presti, MD, PhD


July 02, 2021

Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center.

DR. JOHN WHYTE: Welcome, everyone. I'm Dr. John Whyte, chief medical officer, WebMD, and you're watching Coronavirus in Context. Have you been hearing about the boosters? Are we going to need a booster in the fall? I'm not so sure. And to help provide some insights, I've gone to one of the experts, Dr. Rachel Presti. She's an associate professor of infectious disease at Washington University, St. Louis, and an author of a study that looked about the durability of the mRNA vaccine. Dr. Presti, thanks for joining me.

DR. RACHEL PRESTI: It's nice to be here. Thank you.

WHYTE: Well, let's get right to it, because everybody wants to know how long this immunity lasts. Are we going to need a booster? Does it protect against the variants? Your study recently came out in the journal Nature. I want you to describe it to our viewers and what you found.

PRESTI: So what we looked at was people who had gotten the Pfizer vaccine. So I want to be very, very clear that the only vaccine we looked at was the Pfizer vaccine. So we looked at people who were eligible to get that vaccine very early. So we started enrolling people in December or January, and we looked at two different things.

So initially, we looked at blood and looked at the B cell produced, the antibody cells-producing cells, the B cells in the blood, over time. And then in some of the participants, we also looked at what is happening in the lymph nodes. And what we found was in the blood, you see good antibody responses that's already sort of been seen in all of these vaccines. And the interesting thing that is potentially relevant is that it looked like even in people who'd previously been infected with COVID, there was a boost, there was an increase in their response in the blood after getting the vaccine.

So there's been some discussion about whether or not if you had COVID if you still need a vaccine. I think this would suggest that having a vaccine, there's a benefit.

WHYTE: What period of time did you look at?

PRESTI: So starting in December, and then we have data through about March, April. So 12 weeks or so. About 3 months after people had been fully vaccinated. So after they've gotten their two doses, we started looking in the blood.

WHYTE: And what did you conclude? This is the exciting.

PRESTI: So that is what we saw. We saw that people had nice antibody responses but that they also, even more importantly, had B cells in their blood. So antibody-producing cells in their blood, and we saw that they were sort of lasting through that time period.

WHYTE: That's not something we see with all vaccines, correct?

PRESTI: So, you know? In the blood we do -- what we would expect to see with any vaccine is that you get antibodies that are produced in the blood, and then you expect those antibodies in the blood to go down. In the second and more important part of what we did was to look at the lymph nodes. And what we saw in the lymph nodes was antibody-producing cells in the germinal centers of the lymph nodes. And the germinal centers are kind of like training camp or school for B cells.

And what we saw that was sort of surprising was even 12 weeks after the vaccine had gone in the arm, we were still seeing in quite a few of those folks, we were still seeing these cells in the lymph nodes. And what's important about that is the lymph nodes are where your antibodies get better, right? Where they learn how to bind better, where they learn how to make a broader response to variant.

WHYTE: So what's the bottom line? Because some people are saying you can interpret this data, even though it's based on 12 weeks, that the durability the vaccine, the mRNA vaccines, could provide protection for years. Is that what we can conclude, maybe even a lifetime for those people that have been previously infected with COVID?

PRESTI: Yeah, so immunology is still one of those fields where we know a whole lot more about what happens in animals than we do what happens to humans. But the whole point of the immune system is to make an immune response that lasts your whole lifetime. And so I think we get very focused on what's going on in the blood because that's easy to see, right?

But what your immune system is supposed to do when it sees a pathogen is it takes that to the lymph node, it makes a really strong immune response. And then after that, the really good cells will go to the bone marrow, and they make those memory cells that are supposed to last your life.

So we're still trying to figure out the bone marrow part -- we don't have that data yet, but we should, hopefully, have that soon. But what we're seeing in the lymph nodes is they're making a really good response. And I think that's promising that we might have a response that's going to last for a long time.

WHYTE: How long is a long time?

PRESTI: You know, we've only known about this virus for a year, actually a little bit more, well, a year and a half. So scientists don't like predicting the future, but I think it's likely that this is going to be a durable immune response. Having yet to that is, what is the virus going to do?

WHYTE: Sure, with the variants and mutations. But could one reasonably conclude, from your research, that the vaccine effectiveness for the mRNA vaccines could last for years?

PRESTI: I think you could. I think it looks very promising that you at least make an antibody response that is likely to last for quite some time.

WHYTE: So there, Presti, are a lot of people are excited about this research, and it may show us that we don't need boosters, we need a little more time to tell. But others will say, Dr. Presti, it was a very small study. How do we know that this information is going to hold up?

PRESTI: This study gave us a tremendous opportunity that we haven't really had to see how does your immune system work to a new virus and to see it in extreme detail, right? So we were able to look in the blood, but also in the lymph nodes, and hopefully also in the bone marrow. And that's important data.

WHYTE: Well, some encouraging data about how long the mRNA vaccines may provide protection against coronavirus. Dr. Presti, I want to thank you for the research that you're doing to help provide answers to the questions that we're all having.

PRESTI: Thank you very much.

This interview originally appeared on WebMD on July 02, 2021

Follow Medscape on Facebook, Twitter, Instagram, and YouTube


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.